论文部分内容阅读
目的 观察免疫导向化疗治疗术后肺癌以阻抑肺癌复发的临床疗效。方法 采用转铁蛋白受体单抗(TFR-M)与表阿霉素(EADM)、顺铂(DDP)的偶联物对19例术后肺癌进行免疫导向化疗(导向组),并以12例术后肺癌以EADM、DDP的全身化疗(全身组)作对照观察。结果 导向组2年的年控制率(89.5％、73.7％)均高于全身组(33.3％、8.3％);其年复发率(10.5％、26.3％)均明显低于全身组(66.7％、91.7％)。导向组的中位生存期(24.6个月)是全身月(12.2个月)2倍多。结论 应用TFR-M为“载体”的免疫导向化疗能把化学抗癌药物专一地导入肺内残留的肺癌细胞处,提高了肺内癌灶局部的化疗药物浓度,是一种疗效好、毒性低的抗癌疗法。
Objective To observe the clinical efficacy of immune-directed chemotherapy for postoperative lung cancer to suppress the recurrence of lung cancer. Methods Immune-guided chemotherapy (guide group) was performed on 19 cases of postoperative lung cancer using conjugates of transferrin receptor monoclonal antibody (TFR-M), epirubicin (EADM), and cisplatin (DDP). Cases of lung cancer with EADM, DDP systemic chemotherapy (systemic group) as a control observation. In the result-oriented group, the annual control rate (89.5%, 73.7%) was higher in the 2-year group than in the systemic group (33.3%, 8.3%); the annual recurrence rate (10.5%, 26.3%) was significantly lower than that of the systemic group (66.7%, 91.7%). The median survival time (24.6 months) of the guidance group was more than twice that of the whole body month (12.2 months). Conclusion Immune-guided chemotherapy with TFR-M as a “carrier” can specifically introduce chemical anticancer drugs into the lung cancer cells remaining in the lungs, increasing the concentration of chemotherapeutic drugs in the local lung cancer foci. It is a good curative effect and toxicity. Low anticancer therapy.